Trials / Completed
CompletedNCT00356395
Safety and Effects of Ramipril Combined With Candesartan
Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Gachon University Gil Medical Center · Academic / Other
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.
Detailed description
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ramipril, candesartan |
Timeline
- Start date
- 2003-08-01
- Completion
- 2006-03-01
- First posted
- 2006-07-26
- Last updated
- 2006-07-26
Source: ClinicalTrials.gov record NCT00356395. Inclusion in this directory is not an endorsement.